Patients with FLT3-TKD-mutated AML have lower white blood cell counts and generally have less-aggressive disease than patients with FLT3-ITD-mutated AML, allowing additional time for workup and screening for trials. This evidence concerns the gene FLT3 and acute myeloid leukemia.